Israel Medical Association Journal

Background: Studies have shown that approximately half of the female population may experience some degree of pelvic organ prolapse (POP) during their lifetime, although only 3–6% report symptomatic prolapse.

Objectives: To evaluate the clinical and adverse outcomes associated with transvaginal repair using partially absorbable lightweight polypropylene Seratom PA MR MN® mini mesh for enhanced apical support in the treatment of advanced POP.

Methods: A retrospective study was conducted on 114 patients who underwent transvaginal repair with the Seratom partially absorbable lightweight polypropylene mini mesh between August 2013 and January 2016. Data collected included demographic, surgical, adverse symptoms, and anatomical characteristics assessed via the modified Pelvic Organ Prolapse Quantification system (POP-Q). Postoperative pain was assessed using the Visual Analog Scale.

Results: Significant improvements were observed in POP-Q measurements (P-value < 0.001). Subjective outcomes demonstrated significant pre- to 4-month postoperative reductions in urinary stress incontinence and overactive bladder (P < 0.001). No cases of mesh erosion were reported. Immediate complications included bleeding (3.5%), fever (1.7%), and urinary obstruction (0.9%). The recurrence rate was 12.3%. Patient satisfaction scores were consistently high, with an average of 95.96% at 1 month, 94.73% at 4 months, and 91.33% at the most recent follow-up.

Conclusions: Transvaginal repair with the Seratom PA MR MN® partially absorbable mini mesh demonstrated significant improvements in anatomical and subjective outcomes, with few complications, and low recurrence rates. Further studies are necessary to validate these outcomes and optimize patient selection.

Background: Serasis® (Serag-Wiessner KG, Naila, Germany) is a light-weight mid-urethral sling for treating stress urinary incontinence (SUI). Its insertion is considered less traumatic than other mid-urethral slings.

Objectives: To define postoperative outcomes following Serasis implantation. To compare the efficacy and complication rates of the implant to those of other common techniques.

Methods: Our retrospective study evaluated patients who underwent Serasis mid-urethral sling surgery for SUI. Data were collected from medical records prior to and at the time of surgery and by telephonic interview for postoperative pain and complications. Follow-up of patients was performed for up to one year postoperatively. Patients rated pain or discomfort according to the Visual Analogue Scale (VAS). The primary outcome was the development of early postoperative pain during the first month after surgery. Secondary outcomes were relief of SUI symptoms, groin pain or discomfort, and other postoperative complications up to 12 months after surgery.

Results: The study cohort included 50 consecutive patients aged 31 to 68 years. All patients underwent Serasis implantation procedures by a single surgeon and completed interviews. In total, 35 patients underwent concomitant anterior colporrhaphy. In the immediate postoperative period and at one month after the procedure, complaints were mild. No complaints were recorded during the 12-month follow-up period. Overall, 90% and 92% of the patients were free of SUI symptoms at one month and 12 months after surgery, respectively.

Conclusions: Serasis mid-urethral sling is safe, effective, and associated with mild postoperative pain and a low incidence of complications.